arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2006-12-3-232-236arthyper-1072Research ArticleОБЗОРREVIEWИзоптин СР 240 - эффективный антигипертензивный и антиишемический препаратIsoptin SR 240 - effective antihypertensive and antiishemic medicationМаколкинВ. И.MakolkinV. I.noemail@neicon.ruМосковская медицинская академия им. И.М.СеченоваРоссияMoscow Sechenov Medical academyRussian Federation200628062006123232236Copyright © Маколкин В.И., 20062006Маколкин В.И.Makolkin V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1072

В обзоре представлены данные о высокой антигипертензивпой эффективности и безопасности изоптина СР у больных артериальной гипертензией. Показаны результаты многочисленных сравнительных исследований, доказавших преимущества применения изоптина СР, обусловленные его метаболической нейтральностью, симпатоли-тическим и нефропротективным эффектами.

The review describes data about high antihypertensive efficacy and safety of isoptin SR in patients with arterial hypertension. The results of numerous comparative studies show advantages of isoptin SR related to its metabolic neutrality, symphatolvtic and nephroprotective effects.

антигипертензивная эффективностьсимпатическая нервная системаметаболические влиянияantihypertensive efficacysymphatic nervous systemmetabolic effectReferencesA.Fleckenstein Verapamil. A Drug on the Threshold of the Next Decade // Wissenschaftenverlag Wellingsbüttel GmbH.-1992,- p.9-18.A.Fleckenstein Verapamil. A Drug on the Threshold of the Next Decade // Wissenschaftenverlag Wellingsbüttel GmbH.-1992,- p.9-18.Messerli F.H. //там же.Ч - p.70-82.Messerli F.H. //там же.Ч - p.70-82.Novo S., Alaimo G., Abrignani M.G., Longo B., Muratore G., Strano A. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness. Journal of Cardiovascular Pharmacology 1989; 13 (Suppl. 4): S38-S41.Novo S., Alaimo G., Abrignani M.G., Longo B., Muratore G., Strano A. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness. Journal of Cardiovascular Pharmacology 1989; 13 (Suppl. 4): S38-S41.Safar M., Benetos A., Juvin Ph. et al. Multicentre trial of the antihypertensive efficacy and safety of Verapamil SR. Act. med. Int. - l’Hypertension 1990; 2: 3-7.Safar M., Benetos A., Juvin Ph. et al. Multicentre trial of the antihypertensive efficacy and safety of Verapamil SR. Act. med. Int. - l’Hypertension 1990; 2: 3-7.Holzgreve H., Distier, Michaelis J., Philipp Th., Wellek S. Verapamil versus hydrochlordthiazide in the treatment of hvpertension: results of long term double blind comparrative trial. Br. Med. J. 1989; 299: 881-886.Holzgreve H., Distier, Michaelis J., Philipp Th., Wellek S. Verapamil versus hydrochlordthiazide in the treatment of hvpertension: results of long term double blind comparrative trial. Br. Med. J. 1989; 299: 881-886.Stalmach W.J., Rush D.R., Brücker P.C., Holverson H., Huffmann B.L., Kane W.J., Ryan M.F. Managing hypertension in family practice: a nationwide collaborative study of the use of four antihypertensives in the treatment of inild-to-moderate hypertension. J. Amer. Fam. Pract. 1989; 2:172-190.Stalmach W.J., Rush D.R., Brücker P.C., Holverson H., Huffmann B.L., Kane W.J., Ryan M.F. Managing hypertension in family practice: a nationwide collaborative study of the use of four antihypertensives in the treatment of inild-to-moderate hypertension. J. Amer. Fam. Pract. 1989; 2:172-190.Libretti A., Catalono M. on behalf of the SLIP study gropup. Lipid profile during antihypertensive treatment - the SLIP study. Drugs 1993; 46 (Suppl. 2): 16-23.Libretti A., Catalono M. on behalf of the SLIP study gropup. Lipid profile during antihypertensive treatment - the SLIP study. Drugs 1993; 46 (Suppl. 2): 16-23.Agabiti Rosei E., Dal Plau C., Leonetti G. et al. The verapamil in hypertension and atherosclerosis study (VHAS): results of longterm randomised treatment with either verapamil or chlorthalidone oncarotidintima-mediathickness.J. Hypertens. 1997; 15:1337-1344.Agabiti Rosei E., Dal Plau C., Leonetti G. et al. The verapamil in hypertension and atherosclerosis study (VHAS): results of longterm randomised treatment with either verapamil or chlorthalidone oncarotidintima-mediathickness.J. Hypertens. 1997; 15:1337-1344.Zanchetti A., Magnani B., Dal Plau C. et al. Clinical results of the verapamil in hypertension and atherosclerosis study (VHAS). J. Hypertens. 1998; 16:1667-1676.Zanchetti A., Magnani B., Dal Plau C. et al. Clinical results of the verapamil in hypertension and atherosclerosis study (VHAS). J. Hypertens. 1998; 16:1667-1676.Bakris G.L., Copley J.B., Vicknair N. et al. Verapamil SR has similar nephroprotective properties to lisinopril and is significantly better in comparison to atenolol. Kidney International, vol.50 (1996),1641-1659.Bakris G.L., Copley J.B., Vicknair N. et al. Verapamil SR has similar nephroprotective properties to lisinopril and is significantly better in comparison to atenolol. Kidney International, vol.50 (1996),1641-1659.Lefrandt J.D., van Roon A.M., van Gessel et al. Improved Short-Term Blood Pressure Control by treatment with calcium antagonists in perients with mild or moderate hypertension. J Hypertension 1999, 17 (Suppl.3).Lefrandt J.D., van Roon A.M., van Gessel et al. Improved Short-Term Blood Pressure Control by treatment with calcium antagonists in perients with mild or moderate hypertension. J Hypertension 1999, 17 (Suppl.3).Gillman M.W. et al. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 1993; 125:1148-1154. ОБЗОРGillman M.W. et al. Influence of heart rate on mortality among persons with hypertension: The Framingham Study. Am Heart J 1993; 125:1148-1154. ОБЗОРGrossman E., Messerli F.H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. AmJ Cardiol 1997; 80:1453-1458.Grossman E., Messerli F.H. Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. AmJ Cardiol 1997; 80:1453-1458.Halperin A.K. A Comparison of the Effects of Nifedipine and Verapamil on Exersice Performane in Patients With Mild to Moderate Hypertension. American Journal of Hypertension. 1993; 6: 1025-1032.Halperin A.K. A Comparison of the Effects of Nifedipine and Verapamil on Exersice Performane in Patients With Mild to Moderate Hypertension. American Journal of Hypertension. 1993; 6: 1025-1032.Palmer A., Fketocher A., Hamilton G., Muriss S., Bulpitt O. A comparison of verapamil and nifedipine on quality of life. Brit J Clin Pharmacol 1990; 30:365-370.Palmer A., Fketocher A., Hamilton G., Muriss S., Bulpitt O. A comparison of verapamil and nifedipine on quality of life. Brit J Clin Pharmacol 1990; 30:365-370.Арабидзе Г.Г., Рогоза A.H., Дмитриев B.B. и соавт. Изоп-тин-ретард 240 мг при лечении мягкой и умеренной артериальной гипертонии. Тер. архив, 1993; 9: 50-52.Арабидзе Г.Г., Рогоза A.H., Дмитриев B.B. и соавт. Изоп-тин-ретард 240 мг при лечении мягкой и умеренной артериальной гипертонии. Тер. архив, 1993; 9: 50-52.Арабидзе Г.Г., Дмитриев В.В., Рогоза А.Н. Новый подход к оценке эффективности гипотензивной терапии у больных мягкой и умеренной артериальной гипертонией на примере применения Изоптина-ретарда. Клин, медицина, 1994; 5: 27-30.Арабидзе Г.Г., Дмитриев В.В., Рогоза А.Н. Новый подход к оценке эффективности гипотензивной терапии у больных мягкой и умеренной артериальной гипертонией на примере применения Изоптина-ретарда. Клин, медицина, 1994; 5: 27-30.Глотов М.H., Пшеницин А.И., Мазур H.A., Малов А.Г. Оценка влияния Изоптина-ретарда на центральную гемодинамику и показатели диастолической функции желудочка у больных гипертонической болезнью. Тер. архив. 1993; 9: 29-31.Глотов М.H., Пшеницин А.И., Мазур H.A., Малов А.Г. Оценка влияния Изоптина-ретарда на центральную гемодинамику и показатели диастолической функции желудочка у больных гипертонической болезнью. Тер. архив. 1993; 9: 29-31.Маколкин В.И., Подзолков В.И. Изоптин. Эволюция взглядов от Флекенштейна до наших дней. Тер. архив 1998; 10:79-81.Маколкин В.И., Подзолков В.И. Изоптин. Эволюция взглядов от Флекенштейна до наших дней. Тер. архив 1998; 10:79-81.Подзолков В.И., Корпус Д.Л., Косева К.И., Маколкин В.И. Эффективность Изоптина SR у больных гипертонической болезнью. Клин, фармакология и терапия, 1998; 7(4): 37-38.Подзолков В.И., Корпус Д.Л., Косева К.И., Маколкин В.И. Эффективность Изоптина SR у больных гипертонической болезнью. Клин, фармакология и терапия, 1998; 7(4): 37-38.Кукес В.Г., Красных Л.М., Теплоногова Е.В. Применение Изоптина SR 240 в лечении артериальной гипертонии. Клиническая фармакология и терапия 1998; 8:50-52.Кукес В.Г., Красных Л.М., Теплоногова Е.В. Применение Изоптина SR 240 в лечении артериальной гипертонии. Клиническая фармакология и терапия 1998; 8:50-52.Pepine C.J., Handberg E., Cooper-De-Hoff R. et al. A Calcium Antagonist vs Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA, December 3, 2003-Vol. 290,№ 21:2805-2816.Pepine C.J., Handberg E., Cooper-De-Hoff R. et al. A Calcium Antagonist vs Non-Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. The International Verapamil-Trandolapril Study (INVEST): A Randomized Controlled Trial. JAMA, December 3, 2003-Vol. 290,№ 21:2805-2816.Silber S., Vogler A., Theisen К. Equal anti-ischemic properties of isosorbide dinitrate plus propranolol - a randomised, double-blind and crossover study. Z. Kardiol., Suppl.3 (1986), 100-105.Silber S., Vogler A., Theisen К. Equal anti-ischemic properties of isosorbide dinitrate plus propranolol - a randomised, double-blind and crossover study. Z. Kardiol., Suppl.3 (1986), 100-105.Pallone N.M. Effect of Calcium Antagonists in the Treatment of Silent Ischemic Heart Disease. Curr. Ther. Res., 45 (1989), 339-346.Pallone N.M. Effect of Calcium Antagonists in the Treatment of Silent Ischemic Heart Disease. Curr. Ther. Res., 45 (1989), 339-346.Rehnqvist N., Hjemdahl P., Billing E. et al. Effect of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm. Eur. Heart J. 1996; 17: 76-81.Rehnqvist N., Hjemdahl P., Billing E. et al. Effect of metoprolol vs. verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm. Eur. Heart J. 1996; 17: 76-81.Jesperson C.M., Fischer Hansen J. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-785.Jesperson C.M., Fischer Hansen J. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-785.Rengo F., Carbon P., Pathor M. et al. A conrolled trial in patients after myocardial infarction: results of the Calcium antagonist Reinfarction Italian Studv. Am. J. Cardiol. 1996; 77: 365-369.Rengo F., Carbon P., Pathor M. et al. A conrolled trial in patients after myocardial infarction: results of the Calcium antagonist Reinfarction Italian Studv. Am. J. Cardiol. 1996; 77: 365-369.Hoberg E., Dietz R., Frees U. et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br. Heart J. 1994; 71: 254-260.Hoberg E., Dietz R., Frees U. et al. Verapamil treatment after coronary angioplasty in patients at high risk of recurrent stenosis. Br. Heart J. 1994; 71: 254-260.

The authors declare that there are no conflicts of interest present.